Correction: The MYH7 c.2770G > A (p.Glu924Lys) mutation exhibits phenotypic heterogeneity in hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM): a case report. [PDF]
Han Y +5 more
europepmc +1 more source
Neohesperidin alleviates doxorubicin‐induced cardiotoxicity by inhibiting METTL3‐mediated m6A modification of Nrf2 mRNA, thereby regulating Nrf2 and suppressing ferroptosis. ABSTRACT Doxorubicin (DOX) has antitumor efficacy, but its clinical application is restricted by multiple side effects, especially cardiotoxicity.
Ruijia Wen +9 more
wiley +1 more source
The evolving landscape of restrictive cardiomyopathy treatment: clinical trial trends and future directions. [PDF]
Deng B, Liu W.
europepmc +1 more source
Transient restrictive cardiomyopathy in cats: first reported case series. [PDF]
Poissonnier C +9 more
europepmc +1 more source
Estimated alcohol‐attributable health burden in New Zealand: A comparative risk assessment
Abstract Aims To estimate the alcohol‐attributable morbidity and mortality in New Zealand (NZ) as measured by deaths, cancer registrations, hospitalisations and Accident Compensation Corporation (ACC) injury claims. Design Comparative risk assessment methodology.
Tim Chambers +4 more
wiley +1 more source
A case report of MYH7 mutation-induced restrictive cardiomyopathy. [PDF]
Zhang S, Zhao W.
europepmc +1 more source
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke +5 more
wiley +1 more source
Constrictive-effusive pericarditis and epicarditis as a cause of restrictive cardiomyopathy associated with Dirofilaria repens infection in a dog. [PDF]
Szaluś-Jordanow O +9 more
europepmc +1 more source
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source

